Business
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for t...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n May 14, 2024\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that initial results from the ongoing Phase\n \n 1b\n \n study of EP-104GI for the treatment of eosinophilic esophagitis will be presented at the upcoming Digestive Disease Week (\"DDW\") Annual Meeting 2024.\n \n \n The meeting is being held in\n \n Washington, D.C.\n \n , from\n \n May 18-21, 2024\n \n . Eupraxia's Chief Scientific Officer,\n \n Amanda Malone\n \n , PhD, will present the poster presentation on\n \n May 18, 2024\n \n .\n \n \n \n Presentation Details:\n \n \n \n \n \n \n \n \n Abstract:\n \n \n \n \n \n \n 4031521\n \n \n \n \n \n \n \n \n Presentation Title:\n \n \n \n \n \n \n \n Initial Results From RESOLVE, An Ongoing Phase 1b/2a Dose- Escalation Study Of EP-104GI (Long-Acting Fluticasone\n \n Propionate Injectable Suspension) For Eosinophilic\n \n Esophagitis\n \n \n \n \n \n \n \n \n \n \n Session Type:\n \n \n \n \n \n \n Poster Session\n \n \n \n \n \n \n \n \n Session Title:\n \n \n \n \n \n \n Eosinophilic Esophagitis and Gastroenteritis: Clinical\n \n \n \n \n \n \n \n \n Session Date & Time:\n \n \n \n \n \n \n May 18, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4)\n \n \n \n \n \n ...